Company Performance - Hologic (HOLX) ended the recent trading session at $65.11, demonstrating a +1.31% change from the preceding day's closing price, outperforming the S&P 500's daily gain of 0.8% [1] - The stock has climbed by 0.88% in the past month, which is below the Medical sector's gain of 3.12% and the S&P 500's gain of 5.12% [1] Earnings Projections - Hologic's upcoming earnings per share (EPS) are projected to be $1.05, reflecting a 0.94% decrease from the same quarter last year [2] - The latest consensus estimate predicts revenue to be $1.01 billion, indicating a 0.39% decrease compared to the same quarter of the previous year [2] - Full-year Zacks Consensus Estimates call for earnings of $4.19 per share and revenue of $4.08 billion, representing year-over-year changes of +2.7% and +1.16%, respectively [3] Analyst Estimates and Rankings - Recent changes to analyst estimates for Hologic suggest a direct relationship with upcoming stock price performance, with positive estimate revisions indicating optimism about the business outlook [4][3] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Hologic at 4 (Sell) [5] - Over the past month, the Zacks Consensus EPS estimate has shifted 0.11% downward [5] Valuation Metrics - Hologic is trading at a Forward P/E ratio of 15.32, which is a discount compared to the average Forward P/E of 27.05 for its industry [6] - The company has a PEG ratio of 2.36, compared to the industry average PEG ratio of 2.25 [6] Industry Context - The Medical - Instruments industry, part of the Medical sector, holds a Zacks Industry Rank of 181, positioning it in the bottom 27% of all 250+ industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]
Hologic (HOLX) Surpasses Market Returns: Some Facts Worth Knowing